IDO1 Effectively Reduces Autoimmune Disease Symptoms in Study

Tryptophan is an amino acid with important biological functions, but it must be properly regulated. It can be broken down by an enzyme called Indoleamine-2,3-dioxygenase 1 (IDO1). When tryptophan is metabolized by IDO1, it affects the function of various T cells. If IDO1 is not functioning properly, there is an increased risk of T cell-mediated autoimmune diseases in humans. Until now, research on the therapeutic potential of IDO1 in treating autoimmune diseases has been limited. However, a recent paper published in Cell Reports Medicine, titled “mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity,” addresses this issue.

In the study, scientists used lipid nanoparticles to deliver human mRNA for IDO1 into cells of three rodent models of T cell-mediated autoimmune diseases: experimental autoimmune encephalomyelitis, rat collagen-induced arthritis, and acute graft-versus-host disease. The delivery of IDO1 mRNA led to the production of the IDO1 protein and a reduction in tryptophan levels. As a result, all three rodent models showed improved disease symptoms.

More research is needed to determine whether this approach would be safe and effective in treating T cell-mediated autoimmune diseases in humans.

Citation:

Kenney, L. L., Chiu, R. S.-Y., Dutra, M. N., Wactor, A., Honan, C., Shelerud, L., Corrigan, J. J., Yu, K., Ferrari, J. D., Jeffrey, K. L., Huang, E., & Stein, P. L. (2024). MRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2024.101717